SEL Pharmacological Management of Neuropathic Pain in Adults in primary care

All patients should be reviewed at 8 weeks (unless otherwise stated) after treatment has been started to establish ongoing need to continue

*AMITRIPTYLINE

line

s

line

pd

line

S S

Initiate dose at 10mg/night and gradually up-titrate as tolerated at 2-4 week intervals up to 25mg/night to allow acclimatisation of potential sideeffects. Doses >25mg/night should usually be on the advice of a specialist. Trial for 12 weeks then review.

Relative contraindications to therapy include: recent myocardial infarction, arrhythmia, history of prostatism, or narrow angle glaucoma.

If this is contra-indicated, or ineffective/not tolerated after trial period, stop and replace with 2nd line treatment. If duration of treatment < 6-8 weeks, withdrawal effects unlikely. If duration of treatment > 6-8 weeks, wean off over 4 week period.

**GABAPENTIN

See dosing titration schedule. Based on patient's response, gradually titrate up (most achieve max pain relief below 2700mg/day) if renal function normal (see product SPC for dosing guidance in renal impairment). Stop when patient reaches pain relief goals, or experiences intolerable side effects. Advise patients that they may not feel pain relief straightaway, as they are building tolerability to the medication.

If this is contra-indicated, ineffective or not tolerated, stop and replace with 3rd line treatment.

**PREGABALIN

Start dose at 50mg TWICE DAILY (see product SPC for dosing guidance in renal impairment) and titrate upwards depending on patient's response. Stop when patient reaches treatment goals or experience side effects. Max. dose is 300mg twice daily.

OR

DULOXETINE - 1st line for neuropathic pain in diabetic peripheral neuropathy but avoid in severe renal impairment (CrCl <30ml/min). Consider amitriptyline instead. Starting dose 30mg DAILY - based on patient's response, gradually titrate upwards to 120mg daily (in two divided doses). Response should be seen within 2-4 weeks. Review patient at 8 weeks after initiation and every 3 months thereafter to establish ongoing need to continue. If ineffective at 8 weeks, discontinue treatment.

If this is contra-indicated, ineffective or not tolerated, go onto combination therapy (4th line)

Combination therapy Check for possible drug interactions - see BNF

Although there is limited evidence for combination therapy, NICE advises using two agents from different classes ahead of considering specialist referral, as it may be helpful if initial drugs were insufficient at reducing pain. May also result in better tolerability because smaller doses of individual drugs are often used when combined with other drugs e.g. sleep is improved with amitriptyline but if suboptimal pain control, add in gabapentin instead of increasing amitriptyline dose.

REFER to Specialist Pain Service if all of the above fails or earlier if response is poor.

Include relevant drug history when referring to pain service (see Prescribing Points on next page). Consider TRAMADOL only for acute rescue therapy if needed whilst awaiting referral. Long term use of tramadol should be only under the advice of a specialist.

NB: Caution in using duloxetine and tramadol together - potential for increased serotonergic effects (see BNF). Tramadol and paracetamol combination products should not be prescribed (see SEL IMOC position statement).

Treatment only to be initiated in specialist care/pain clinic

- **RED listed (all prescribing in hospital only):** • Topical capsaicin 179mg (8%) patch
- Nabilone*
- Ketamine oral solution*
- <u>Botulinum toxin type A</u> for focal neuropathic pain AMBER 2 listed (initiation in hospital only):
- Opioids e.g. Morphine, Oxycodone, Tapentadol
- Antiepileptics for refractory neuropathic pain e.g. Lamotrigine*, Topiramate*, Oxcarbazepine* see GP Information Sheet for more information. For further information, please refer to the <u>SEL Joint Formulary</u>.
- LIDOCAINE 5% (700mg) PLASTERS (AMBER 2) for treatment of *post-herpetic neuralgia* or *focal neuropathic pain with allodynia.

Following stabilisation, continuation in primary care should involve an individual management plan. The specialist must specify duration of treatment and clear directions for reviews. See product SPC and SEL IMOC position statement.

Localised neuropathic pain

For management of localised neuropathic pain including superficial, small fibre neuropathies, post herpetic neuralgia and painful diabetic peripheral polyneuropathy, consider:

CAPSAICIN 0.075% CREAM (recommended for patients who wish to avoid/cannot tolerate oral treatments). Apply a peasized amount up to 4 times daily for 6-8 weeks, then review.

Trigeminal neuralgia

CARBAMAZEPINE – Start dose at 100mg twice daily and slowly titrate the dose based on response in steps of 100 - 200 mg every 2 weeks until pain is relieved. Maximum dose is 1600mg daily. See also MHRA updated safety advice on antiepileptic drugs in pregnancy.

If carbamazepine is inappropriate, ineffective, or not tolerated, seek specialist advice. Do *not* offer any other drug treatment (e.g. oxcarbazepine [AMBER 2 listed]) unless advised to do so by a specialist.

For further information, please refer to NICE CKS on trigeminal neuralgia.

- **Please see PHE guidance on pregabalin and gabapentin use leading to dependence and potential abuse PHE-NHS England Pregabalin and Gabapentin Advice Dec 2014 South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London: South East London Clinical Commissioning Group (covering the boroughs of Bexley/Bromley/Greenwich/Lambeth/Lewisham and Southwark) and GSTET/KCH/SLAM/ & Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust
 - Approval date: June 2022 Review date: June 2024 Not to be used for commercial or marketing purposes. Strictly for use within the NHS only.

Amitriptyline dosing Instructions

- Counsel patient that it can take up to 12 weeks to achieve response.
- Advise patient to take 1-2 hours before bed; if morning sedation is problematic, the dose may be taken earlier in the evening.
- If excessive hangover effect or sedation is an issue, only in this instance should ***NORTRIPTYLINE** tablets be considered, using the same dose instructions as amitriptyline.


Gabapentin dosing titration schedule

	Week 1	Week 2	Week 3	Week 4		
Morning	100mg	200mg	300mg	400mg		
Midday	100mg	200mg	300mg	400mg		
Night	100mg	200mg	300mg	400mg		

Consider gradual titration in week 1 starting with 100mg at night on Day 1, slowly titrating to 100mg three times daily by Day 5. Max 3600mg/day Side effects (mainly cognitive) often limit dose incrementation. Consider asymmetrical dosing (more in evening than daytime) if these occur.

Cross tapering from gabapentin to pregabalin/duloxetine

- When cross tapering from gabapentin \rightarrow pregabalin or gabapentin \rightarrow duloxetine, the dose of gabapentin should be reduced by 300mg every 4 days until patient is on 300mg three times daily.
- Gabapentin dose should continue to be withdrawn, whilst commencing 3rd line treatment (see page 3 for further information).
- For dose initiation and titration schedules for pregabalin and duloxetine, please refer to Appendix 2.





^{*}Licensed medicines being recommended for off-label use

Prescribing Points

- When initiating treatment, the prescriber should agree a plan with the patient and provide them with a British Pain Society leaflet (see page 3).
- The 10-point Numeric Rating Scale (NRS) is a pain assessment scale which can be used to measure baseline pain and subsequently to assess whether treatment is effective (see Appendix 1).
- The anticholinergic burden (ACB) of the patient's current medication should be assessed before starting treatment using ACB scales, where a score is assigned to each drug based on its anticholinergic potency. The higher the score, the greater the anticholinergic effect. The South London and Maudsley Anticholinergic Effect on Cognition (AEC) scale (available as a webbased app at www.medichec.com) is the preferred ACB scale to use, as its development is more robust and evidence based compared to other ACB scales. Using this feature, prescribers can determine AEC score of a particular medication, add each medication to a list to calculate the total score and email a summary or export as a PDF.
- Caution with concomitant use of opioids in relation to potential sedative and cognitive side effects. Gabapentinoids are opioid-sparing due to synergistic effect meaning less opioid is effectively needed with combined use opioid dose reduction may be advised to reduce risk of respiratory depression, accidental drug overdose or death (see MHRA advice). Risk of harm with opioids increases substantially at doses above oral morphine equivalent of 120mg/day. Take caution regarding the dependency-forming nature of opioids, regular review required see <u>SEL IMOC Pharmacological Management of Adult Non-Cancer Chronic Pain in Primary care</u> for more information.

See also - Guidance for healthcare professionals on drug driving.

- Realistic goals need to be set, as pain free status is not usually achievable and 20-50% reduction in pain is a commonly used end-point in clinical trials.
- The goal of neuropathic pain treatment is to support initial symptomatic relief for people so that they are sufficiently able to engage in <u>non-pharmacological treatment</u> such as light exercise, physiotherapy, relaxation techniques and rehabilitation. NHS exercise advice, including exercise videos, can be accessed at https://www.nhs.uk/live-well/exercise/free-fitness-ideas/
- Consider referral to a dietician for advice on blood sugar control in patients with diabetic peripheral neuropathy.
- Aim to trial amitriptyline for total 12 weeks where possible, then review. For all other steps, trial on maximum tolerated dose for <u>8 weeks</u> (or earlier where relevant) for evidence of benefit before moving to the next step. During this time, patients should be encouraged to engage with non-pharmacological strategies as listed above.
- <u>Clinical review (at 8 weeks or earlier if applicable) should include:</u>

	Assessment of pain reduction and adverse effects	-	Mood (in particular, possible depression and/or anxiety)
-	Daily activities and participation (such as ability to	-	Overall improvement as reported by the patient
	work and drive)		
-	Quality of sleep	-	Whether there is a continued need for treatment

non-

- Referral to specialist pain service should be considered at any stage if:
 - Patient has severe pain or
 - Pain significantly limits their daily activity and participation or
 - Their underlying health condition has deteriorated.
- On the GP referral form to the pain service, information on what drug treatment (pharmacological and pharmacological) has been trialled so far in primary care should be included. This should outline:
 - Drug history of what patient has trialled so far (including dose and strength of treatment)
 - Whether drug treatment was successful or not
 - Dose at which drug treatment was discontinued, and reason for discontinuation (where relevant)
- Appendix 3 shows example of good practice on the level of information that should be provided as standard within clinic letters from the pain service team to GP practices for patients who have been started on treatment for neuropathic pain.
- Pharmacological therapy should not be considered a long-term management strategy and efforts should regularly be made to reduce the dosage and gradual withdrawal of treatment, particularly as many treatments are associated with safety or dependence issues following long-term use.
- At any step when the pain is in <u>remission</u> (remain pain free for 8 weeks) after discussion and review with the patient the dosage can be reduced and gradually withdrawn if deemed appropriate (see next page).
- For more information about cautions/contraindications of neuropathic pain treatment, please refer to the medication's summary of product characteristics (SPC).

Treatment withdrawal regimes

Drug name	Recommendation strategy for withdrawal					
Amitriptyline/Nortriptyline	Reduce daily dose by 10mg each week					
Gabapentin	Reduce total daily dose by 300mg every 4 days					
(total daily dose > 900mg)						
Gabapentin	Reduce total daily dose by 100mg every 4 days					
(total daily dose ≤ 900mg)						
Duloxetine	Reduce dose by 30mg every 3-4 days, then stop.					
Pregabalin	Reduce total daily dose by 50mg every week					
Lidocaine plasters	See South East London Guide to Deprescribing Lidocaine 5%					
	Plasters in Primary Care					

Taper the withdrawal regimen to take account of dosage and discontinuation symptoms (see Appendix 2). If complete withdrawal of treatment is not successful, the patient should continue on the last dose in the reduction regimen at which pain was tolerable and they should be engaged in discussion about long term goals and non-pharmacological management. If the patient has remained pain-free for 8 weeks afterwards, dose reduction or withdrawal should be reattempted.


The following <u>British Pain Society patient leaflets</u> can support patients on specific neuropathic pain treatment options. It includes information on how their medication works, as well as a table to fill in regarding their individualised dosing schedule, in order to support titrating dose upwards/downwards.

- Amitriptyline patient leaflet for pain
- Nortriptyline patient leaflet for pain
- Duloxetine patient leaflet for pain
- Pregabalin patient leaflet for pain
- Gabapentin patient leaflet for pain

For more information and useful resources, which includes eLearning packages:

British Pain Society resources	https://www.britishpainsociety.org/about/articles- and-reports/
Faculty of Pain Medicine - eLearning for healthcare professionals	https://fpm.ac.uk/e-pain
ESCAPE-pain app – a useful tool for patients in managing their pain	https://escape-pain.org/escape-pain-app
Paintoolkit.org - designed for people who live with persistent pain and Healthcare teams who support them	https://www.paintoolkit.org/
Guys and St Thomas Medicines Information service	Telephone: 0207 188 8748 Email: medicinesinformation@gstt.nhs.uk

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London: South East London Clinical Commissioning Group (covering the boroughs of Bexley/Bromley/Greenwich/Lambeth/Lewisham and Southwark) and GSTFT/KCH/SLAM/ & Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust.



2 or more points/centimetres reduction indicates a significant benefit

Indicated for adults and children (>9 years old) in all patient care settings in which patients are able to use numbers to rate the intensity of their pain. This may also apply to children younger than 9 years where they have a firm understanding of numbers. The NRS consists of a straight horizontal line numbered at equal intervals from 0 to 10 with anchor words of "no pain", "moderate pain" and "worst pain". (Breivik H et al. (2008) Assessment of pain. Br J Anaesth. 101 (1): 17-24)

Appendix 2: Dose titration tables for neuropathic pain treatment

For up to date information about cautions/contraindications of neuropathic pain treatment, please refer to the medication's summary of product characteristics (SPC).

Amitriptyline or Nortriptyline

Up-titration schedule						Down titration schedule if ineffective
 Local pain consultants have advised maxir 	If less than 8 weeks, withdrawal effects unlikely.					
 Take 1-2 hours before bed to reduce hang 						
 If patient experiences side effects then re- 	If greater than 8 weeks, wean off over 4 week period by					
 Avoid co-prescribing of tramadol as increa 	reducing dose by 10mg each week.					
	Week 1	Week 2	Week 3	Week 4		
Night	10mg	20mg	30mg	40mg		

Gabapentin PHE-NHS England Pregabalin and Gabapentin Advice Dec 2014: Pregabalin or Gabapentin can lead to dependence and may be misused or diverted due to associated euphoric effect and should be avoided in patients with a known or suspected propensity to misuse, divert or become dependent.

 Consider gradual titration in week 1 starting with 100mg at night on Day 1, sl Day 5. Dose should only be increased within the recommended increments (see and treatment goals have not yet been achieved. Local pain consultants have advised that lower starting dose may improve tole reported being sensitive to central nervous system depressant effects of other Although the maximum daily dosage in BNF is 3600mg/day, local pain consultants nervous achieve maximum therapeutic response at 2700mg/day. 	this sho unless rticularly for patients who have on or in the elderly.	ould be stepp observations	ed down by 3 s of emerge ase more grad	<u>er than 900mg daily</u> 00mg every 4 days ont symptoms are ual dose tapering is
achieve maximum therapeutic response at 2700mg/day. Gabapentin initiation scheme		Week 1	Week 2	
Gabapentin initiation scheme	Morning		VVCCK Z	Week 3
		300mg	300mg	
	Midday	300mg		
Week 1 Week 2 Week 3 Week 4	Night	300mg	300mg	300mg
Morning 100mg 200mg 300mg 400mg				
Midday 100mg 200mg 300mg 400mg				
Night 100mg 200mg 300mg 400mg				
Gabapentin dosage in Adults based on Renal Function			dose is <u>less th</u> wn by 100mg	<u>an 900mg daily</u> , this every 4 days.
Creatinine clearance (ml/min) Total Daily Dose in divided doses (mg/day)				
≥ 80 900-3600				
50-79 600-1800				
30-49 300-900				
15-29 150-600mg (150mg = 300mg on alternate days)				
<15 150-300mg (150mg = 300mg on alternate days)				

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London: South East London Clinical Commissioning Group (covering the boroughs of Bexley/Bromley/Greenwich/Lambeth/Lewisham and Southwark) and GSTFT/KCH/SLAM/ & Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust.

Pregabalin *PHE-NHS England Pregabalin and Gabapentin Advice Dec 2014:* Pregabalin or Gabapentin can lead to dependence and may be misused or diverted due to associated euphoric effect and should be avoided in patients with a known or suspected propensity to misuse, divert or become dependent.

Up-titration schedule							Down titrat	tion sched	ule if ineffe	ective		
 Although it is licensed to DAILY, and also improve 	be given in two or three s patient compliance.	e divided dose	es, it is mo	ore cost e	ght to improve tolerability. ffective to prescribe pregal ed a single dose strength of	abalin TWICE		e by 50-75n ted withdra	• ·		ose of 150	mg twice a
for use twice daily (after	using up stock at home	e for titration	doses).					Week 1	Week 2	Week 3	Week 4	Stop
		Week 1	Week 2	Week 3	1		Morning	150mg	75mg	50mg	25mg	and
	Morning			150mg			Night	75mg	75mg	50mg	25mg	review patient
												patient
For older patients (>75 years		npairment: S	Start on 25	-	daily. If creatinine clearand	nce						
<30ml/min, it may be approp) or those with renal in	npairment: S aily dose as p	Start on 25 per table be	img twice elow.	daily. If creatinine clearand	nce						
<30ml/min, it may be approp) or those with renal in riate to give this as a da Dosage of Pregabalin in A	npairment: S aily dose as p	Start on 25 per table be	ing twice elow. nction	daily. If creatinine clearand	nce						
<30ml/min, it may be approp) or those with renal in riate to give this as a da Dosage of Pregabalin in A	npairment: S aily dose as p Adults based o gabalin daily d	Start on 25 per table be n Renal Fur dose	ing twice elow. nction		ice						
<30ml/min, it may be approp) or those with renal in riate to give this as a da Dosage of Pregabalin in A Total pre Starting dose (mg/day)	npairment: S aily dose as p Adults based o gabalin daily d	Start on 25 per table be n Renal Fur dose	Sing twice elow. nction		nce						
<30ml/min, it may be approp Creatinine clearance (ml/min)) or those with renal in riate to give this as a da Dosage of Pregabalin in A Total pre Starting dose (mg/day) 150	npairment: S aily dose as p Adults based o gabalin daily d Maximum dos	Start on 25 per table be n Renal Fur dose	img twice elow. nction () E	Dose regimen	nce						
<30ml/min, it may be approp Creatinine clearance (ml/min) ≥ 60) or those with renal in riate to give this as a da Dosage of Pregabalin in A Total pre Starting dose (mg/day) 150 75	mpairment: S aily dose as p Adults based of gabalin daily d Maximum dos 600	Start on 25 per table be n Renal Fur dose	Sing twice elow. nction () E	Dose regimen 3D or TDS	nce						

Duloxetine avoid if creatinine clearance < 30ml/min. Potential for increased serotonergic effects (see BNF) when duloxetine and tramadol are used together – use with caution.

Up-titration schedule			Down titration schedule if ineffective
SPC states that response to treatment	ment should be seen within	Discontinue if inadequate response at 8 weeks.	
 Review ongoing need at 8 weeks, f Due to the large inter-individual va to 60mg and may benefit from a h 	ariability in duloxetine pla	• Reduce dose by 30mg every 3-4 days, then stop.	
response to initial doce		Where higher doses are required, gradually increase up to an effective dose or the patient's maximum tolerated dose	
Night 30mg	60mg		

Tramadol Potential for <u>increased serotonergic effects (see BNF)</u> when duloxetine and tramadol are used together – use with caution.

Up-titration schedule	Down titration schedule if ineffective
• Initially 50mg TWICE A DAY (50mg at night in the elderly) with increments of 50mg/day every 3 days dependent upon	• If patient does not experience therapeutic benefit, reduce
patient response, up to a maximum of 400mg/day.	dose by 50mg every 3-4 days (this is not evidence based).

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London: South East London Clinical Commissioning Group (covering the boroughs of Bexley/Bromley/Greenwich/Lambeth/Lewisham and Southwark) and GSTFT/KCH/SLAM/ & Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust.



Appendix 3 - Example of care plan for patients being transferred back to general practice

This care plan template is an example of good practice for patients who have been started on neuropathic pain treatment by the pain service. Pain specialists should aim to provide a standardised level of information and details when transferring patients back to their GP. This includes explaining why the treatment has specifically been chosen for the patient, which aims to empower GPs in optimally managing patients on pharmacotherapy treatment for neuropathic pain.

{Insert Address Details}

Date.....

Dear Dr. {GP name}

Your patient has been started on neuropathic pain treatment as outlined in their individualised care plan below. They have been given a supply of this medication *{insert drug name}* for *{X}* days from the date of this letter, and I would be grateful if you could kindly arrange the prescription for this patient after this supply runs out.

Care Plan							
Re: (Insert patient's name)	Hospital no:						
NHS no: DOB:							
Name of specialist:							
Specific disease description (include pain scores):							
Medication details:							
Drug name:	Dose :						
Date of initiation:	Length of treatment:						
Date of next treatment review :							
Treatment aims/goals :							
- To achieve 20-50% reduction in pain							
{Include what this would look like for patient, based on	their current pain experience}						

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London: South East London Clinical Commissioning Group (covering the boroughs of Bexley/Bromley/Greenwich/Lambeth/Lewisham and Southwark) and GSTFT/KCH/SLAM/ & Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust. Approval date: June 2022 Review date: June 2024 Not to be used for commercial or marketing purposes. Strictly for use within the NHS only.

		to consider g	gradually redu	ucing dose	
reatment: {Ple	ase insert rel	levant titratio	on dose sched	lule for medic	cation prescribed}
Initiation so	cheme				
	Week 1	Week 2	Week 3	Week 4	
Morning					_
Midday					
Night					
treatment re	commendat	ions (where	relevant):		
nerapy, and oth	er psycho-so	cial factors to	consider}		
ring should be	e undertake	n by the GP:			
ain service wou	ld follow up p	patient at 8 w	veek period, o	or if GP is exp	ected to do this}
	reatment aims reatment aims reatment: {Ple Initiation se Morning Midday Night treatment re perapy, and oth ring should be	reatment aims/goals} reatment: {Please insert rel Initiation scheme Morning Midday Night treatment recommendat berapy, and other psycho-soc	treatment aims/goals} reatment: {Please insert relevant titration Initiation scheme Week 1 Week 2 Morning Initiation Midday Initiation Night Initiation scheme treatment recommendations (where merapy, and other psycho-social factors to merapy, and other psycho-social factors to merapy, and other psycho-social factors to merapy, and other psycho-social factors to	treatment aims/goals} reatment: {Please insert relevant titration dose sched Initiation scheme Week 1 Week 2 Morning Image: Schedeling Midday Image: Schedeling Night Image: Schedeling treatment recommendations (where relevant): perapy, and other psycho-social factors to consider) ming should be undertaken by the GP:	reatment: {Please insert relevant titration dose schedule for media Initiation scheme week 1 week 2 Morning week 3 Midday week 1 Night week 1 treatment recommendations (where relevant): terapy, and other psycho-social factors to consider}

CRISIS PLAN

Signs/symptoms that require advice from or referral back to pain specialist

If the patient experiences any of these signs or symptoms whilst on therapy – they should report to their GP without delay:

Signs/symptoms the patient may experience whilst on therapy, but can be managed in primary care:

References:

- 1. NICE Clinical Guideline 173 : Neuropathic pain in adults: pharmacological management in non-specialist settings https://www.nice.org.uk/guidance/cg173 November 2013
- Gloucestershire CCG pain guidelines: <u>http://www.gloshospitals.nhs.uk/en/Wards-and-</u> <u>Departments/Departments/Pain-Management/Different-Pains/Nerve-Pain/Draft-Neuropathic-pathway/</u> June 2016
- **3. PrescQIPP Bulletin 119** : Pregabalin in neuropathic pain <u>https://www.prescqipp.info/pregabalin-in-neuropathic-pain/category/80-pregabalin-in-neuropathic-pain</u> *January 2016*
- 4. Mid Essex CCG: Neuropathic pain guidelines June 2016
- 5. Drug Tariff: July 2017
- 6. British National Formulary: BNF British National Formulary NICE
- 7. Electronic Medicines Compendium: <u>Cymbalta 30mg hard gastro-resistant capsules Summary of Product</u> <u>Characteristics (SmPC) - (emc) (medicines.org.uk)</u>